1477 related articles for article (PubMed ID: 29263073)
1. Activity of Ceftolozane-Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae Isolates Collected from Respiratory Tract Specimens of Hospitalized Patients in the United States during 2013 to 2015.
Castanheira M; Duncan LR; Mendes RE; Sader HS; Shortridge D
Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263073
[TBL] [Abstract][Full Text] [Related]
2. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013-2015).
Pfaller MA; Shortridge D; Sader HS; Castanheira M; Flamm RK
Int J Antimicrob Agents; 2018 Feb; 51(2):181-189. PubMed ID: 28993143
[TBL] [Abstract][Full Text] [Related]
3. Antimicrobial Activity of Ceftolozane-Tazobactam Tested Against Enterobacteriaceae and Pseudomonas aeruginosa with Various Resistance Patterns Isolated in U.S. Hospitals (2013-2016) as Part of the Surveillance Program: Program to Assess Ceftolozane-Tazobactam Susceptibility.
Shortridge D; Pfaller MA; Castanheira M; Flamm RK
Microb Drug Resist; 2018 Jun; 24(5):563-577. PubMed ID: 29039729
[TBL] [Abstract][Full Text] [Related]
4. In-vitro activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae isolates recovered from hospitalized patients in Germany.
Seifert H; Körber-Irrgang B; Kresken M;
Int J Antimicrob Agents; 2018 Feb; 51(2):227-234. PubMed ID: 28705666
[TBL] [Abstract][Full Text] [Related]
5. Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12).
Sader HS; Farrell DJ; Castanheira M; Flamm RK; Jones RN
J Antimicrob Chemother; 2014 Oct; 69(10):2713-22. PubMed ID: 24917579
[TBL] [Abstract][Full Text] [Related]
6. Antimicrobial Activity of Ceftazidime-Avibactam against Gram-Negative Bacteria Isolated from Patients Hospitalized with Pneumonia in U.S. Medical Centers, 2011 to 2015.
Sader HS; Castanheira M; Flamm RK
Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28069649
[TBL] [Abstract][Full Text] [Related]
7. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012-15).
Pfaller MA; Bassetti M; Duncan LR; Castanheira M
J Antimicrob Chemother; 2017 May; 72(5):1386-1395. PubMed ID: 28165526
[TBL] [Abstract][Full Text] [Related]
8. Activity of ceftolozane/tazobactam against Gram-negative isolates among different infections in Hong Kong: SMART 2017-2019.
Karlowsky JA; Lob SH; Khan A; Chen WT; Woo PCY; Seto WH; Ip M; Leung S; Wong QW; Chau RWY; DeRyke CA; Young K; Motyl MR; Sahm DF
J Med Microbiol; 2022 Apr; 71(4):. PubMed ID: 35451945
[No Abstract] [Full Text] [Related]
9. Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Australia and New Zealand: Report from an Antimicrobial Surveillance Program (2013-2015).
Pfaller MA; Shortridge D; Sader HS; Flamm RK; Castanheira M
J Glob Antimicrob Resist; 2017 Sep; 10():186-194. PubMed ID: 28735046
[TBL] [Abstract][Full Text] [Related]
10. Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa collected from patients with bloodstream infections isolated in United States hospitals (2013-2015) as part of the Program to Assess Ceftolozane-Tazobactam Susceptibility (PACTS) surveillance program.
Shortridge D; Pfaller MA; Castanheira M; Flamm RK
Diagn Microbiol Infect Dis; 2018 Oct; 92(2):158-163. PubMed ID: 29891184
[TBL] [Abstract][Full Text] [Related]
11.
Goodlet KJ; Nicolau DP; Nailor MD
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923865
[TBL] [Abstract][Full Text] [Related]
12. Assessment of the
Viala B; Zaidi FZ; Bastide M; Dumont Y; Le Moing V; Jean-Pierre H; Godreuil S
Microb Drug Resist; 2019 Nov; 25(9):1325-1329. PubMed ID: 31225764
[No Abstract] [Full Text] [Related]
13. Antimicrobial activity of ceftolozane-tazobactam tested against gram-negative contemporary (2015-2017) isolates from hospitalized patients with pneumonia in US medical centers.
Carvalhaes CG; Castanheira M; Sader HS; Flamm RK; Shortridge D
Diagn Microbiol Infect Dis; 2019 May; 94(1):93-102. PubMed ID: 30642717
[TBL] [Abstract][Full Text] [Related]
14. Comparative activity of newer β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa isolates from US medical centres (2020-2021).
Sader HS; Mendes RE; Arends SJR; Carvalhaes CG; Shortridge D; Castanheira M
Int J Antimicrob Agents; 2023 Apr; 61(4):106744. PubMed ID: 36738849
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa and Enterobacteriaceae recovered in Spanish medical centres: Results of the CENIT study.
Tato M; García-Castillo M; Bofarull AM; Cantón R;
Int J Antimicrob Agents; 2015 Nov; 46(5):502-10. PubMed ID: 26315199
[TBL] [Abstract][Full Text] [Related]
16. Results from the China Antimicrobial Surveillance Network (CHINET) in 2017 of the
Yin D; Wu S; Yang Y; Shi Q; Dong D; Zhu D; Hu F;
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30617091
[TBL] [Abstract][Full Text] [Related]
17. Activity of ceftolozane/tazobactam against a collection of Pseudomonas aeruginosa isolates from bloodstream infections in Australia.
Henderson A; Tan E; McCarthy KL; Paterson DL
Pathology; 2018 Dec; 50(7):748-752. PubMed ID: 30392710
[TBL] [Abstract][Full Text] [Related]
18. Multicenter Evaluation of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Inhibitory Activity against Meropenem-Nonsusceptible Pseudomonas aeruginosa from Blood, Respiratory Tract, and Wounds.
Grupper M; Sutherland C; Nicolau DP
Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28739780
[TBL] [Abstract][Full Text] [Related]
19. Ceftolozane-tazobactam activity against clinical isolates of Pseudomonas aeruginosa from ICU patients with pneumonia: United States, 2015-2018.
Pfaller MA; Shortridge D; Harris KA; Garrison MW; DeRyke CA; DePestel DD; Moise PA; Sader HS
Int J Infect Dis; 2021 Nov; 112():321-326. PubMed ID: 34597763
[TBL] [Abstract][Full Text] [Related]
20. Antimicrobial Activity of Ceftazidime-Avibactam, Ceftolozane-Tazobactam and Comparators Tested Against
Sader HS; Carvalhaes CG; Streit JM; Doyle TB; Castanheira M
Microb Drug Resist; 2021 Mar; 27(3):342-349. PubMed ID: 32762605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
